Table 4.
Antibody prevalence in the primary biliary cirrhosis (PBC) cohort compared to the literature.
| Antigen | M2 | 3E-BPO | Ro52 | RAP55 | gp210 | sp100 | PML | GRASP-1 | GW182 |
|---|---|---|---|---|---|---|---|---|---|
| Frequency % | 82 | 73 | 32 | 28 | 27 | 27 | 17 | 17 | 12 |
| Reported Frequency % | 75–96 | 57 | 25–28 | 57 | 17–25 | 20–30 | 19 | 100 | 50 |
| References | [64] | [65] | [51,53] | [9] | [36,64] | [4,35,64] | [42] | [9] | [6] |
| Antigen | CENP-B | VCP | SS-A/Ro60 | SS-B/La | SLA/LP | dsDNA | GW2 | Scl-70 | PCNA |
|---|---|---|---|---|---|---|---|---|---|
| Frequency % | 11 | 11 | 8 | 6 | 3 | 3 | 2 | 2 | 2 |
| Reported Frequency % | 10–30 | 12 | 30 | 7 | 0·6–4 | 10–17 | n.a. | 0 | n.a. |
| References | [48,66,67] | [19,52] | [53] | [66] | [64,68] | [53,69] | [67] |
| Antigen | Ribo-P | RNP | EEA1 | Chromatin | Ge-1 | Sm | Jo-1 | Histone |
|---|---|---|---|---|---|---|---|---|
| Frequency % | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reported Frequency % | 5 | 5 | n/a | 7–25 | 100 | 24–34 | 24–26 | 81 |
| References | [66] | [67] | [64,66] | [9] | [53,67] | [53,67] | [53] |
EEA1, early endosomal antigen 1; 3E-BPO, branched-chain 2-oxo-acid dehydrogenase complex and 2-oxo glutarate dehydrogenase complex; CENP, centromere; GRASP-1, glutamate receptor interacting protein (GRIP)-associated protein-1; LC-1, liver cytosolic-1 antigen; LKM-1, liver kidney microsomal-1 antigen; M2, mitochondrial antigen–pyruvate dehydrogenase complex; PCNA, proliferating cell nuclear antigen; PML, promyelocytic leukaemia cell antigen; n.a., not available or not published; SLA/LP, soluble liver antigen/liver pancreas antigen; Sm, Smith/U2-U6 ribonucleoprotein antigen; SRP, signal recognition particle; VCP, valosin-containing protein.